Nano-Assemblies Based on Biomacromolecules to Overcome Cancer Drug Resistance
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 139
Special Issue Editor
Special Issue Information
Dear Colleagues,
Overcoming tumor resistance is one of the major challenges encountered in cancer treatment. With the rapid development of nanotechnology in recent years, nano-assemblies have become promising candidates due to their strong potential to overcome the drug resistance of tumors. They have a high degree of adaptability, including size and composition regulation, surface versatility and the possibility of combining multiple therapeutic approaches through a single nanoparticle platform. Among multiple self-assembled component materials, biomacromolecules have attracted ever-growing attention because of their unique molecular structures, natural biocompatibility and multifunctional properties.
This Special Issue will summarize various mechanisms of nano-assembly utilization overcoming cancer drug resistance. The roles and research progress of typical biomacromolecules (such as polysaccharides, proteins and nucleic acids) in nano-assemblies capable of overcoming cancer drug resistance will be described, along with the potential challenges and prospects of the clinical application of biomacromolecule-based nano-assemblies. We welcome both original research articles and reviews. We look forward to receiving your contributions.
Prof. Dr. Hongjing Dou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer drug resistance
- nano-assemblies
- biomacromolecules
- therapy
- diagnosis
- drug controlled release
